| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
Clobenpropit exhibits a pK of 9.44±0.04 for human H3LR and 9.75±0.01 for rat H3LR binding. The affinity of clobenpropit for histamine H1R or H2R is minimal (pK 5.2 and 5.6, respectively) [1]. Clobenpropit has a concentration-dependent effect on [3H]-dopamine transport in SH-SY5Y cells, with a maximal inhibition rate of 82.7±2.8%, IC50 of 490 nM (pIC50 6.31±0.11)[2]. The IC50 for NR1/NR2B receptors is 1 μM, and clobenpropit is a non-competitive, subunit-selective antagonist of recombinant NMDA receptors [2]. When Clobenpropit (50 μM) and Gemcitabine (5 μM) were administered together, Panc-1, MiaPCa-2, and AsPC-1 apoptosis increased dramatically in comparison to the control group [3].
|
|---|---|
| ln Vivo |
Significant tumor growth inhibition was demonstrated by combination therapy with gemcitabine (125 mg/kg intraperitoneally twice a week for 40 days) and chlorprofen (20 μM/kg intraperitoneally every other day for 40 days) [ 3].
|
| Cell Assay |
Apoptosis analysis[3]
Cell Types: Pancreatic cancer cells (Panc-1, MiaPaCa-2 and AsPC-1) Tested Concentrations: 50 μM Incubation Duration: Experimental Results: Gemcitabine (5 μM) combination enhanced apoptosis. |
| Animal Protocol |
Animal/Disease Models: 5weeks old male BALB/c nude mice, Panc-1 xenograft [3]
Doses: 20 μM/kg Route of Administration: intraperitoneal (ip) injection; once every other day for 40 days. Gemcitabine (intraperitoneal (ip) injection twice a week, 125 mg/kg, for 40 days) Experimental Results: Compared with other treatment groups (control group 501±92 mg, gemcitabine 294±46 mg, chlorprofenate 444±167), The combination treatment demonstrated significant tumor growth inhibition. mg, and combination 154 ± 54 mg). |
| References |
|
| Additional Infomation |
Clobenpropit dihydrobromide is a hydrobromide salt obtained by reaction of clobenpropit with two equivalents of hydrobromic acid. An extremely potent histamine H3 antagonist/inverse agonist (pA2 = 9.93). Also displays partial agonist activity at H4 receptors; induces eosinophil shape change with an EC50 of 3 nM. It has a role as a H4-receptor agonist and a H3-receptor antagonist. It contains a clobenpropit(2+).
|
| Molecular Formula |
C14H19BR2CLN4S
|
|---|---|
| Molecular Weight |
470.6535
|
| Exact Mass |
467.938
|
| Elemental Analysis |
C, 35.73; H, 4.07; Br, 33.95; Cl, 7.53; N, 11.90; S, 6.81
|
| CAS # |
145231-35-2
|
| Related CAS # |
Clobenpropit;145231-45-4
|
| PubChem CID |
11213569
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
205 °C
|
| LogP |
5.86
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
22
|
| Complexity |
306
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Br[H].Br[H].ClC1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])/N=C(/N([H])[H])\SC([H])([H])C([H])([H])C([H])([H])C1=C([H])N=C([H])N1[H]
|
| InChi Key |
JIJQPEZAVLJZBO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H17ClN4S.2BrH/c15-12-5-3-11(4-6-12)8-18-14(16)20-7-1-2-13-9-17-10-19-13;;/h3-6,9-10H,1-2,7-8H2,(H2,16,18)(H,17,19);2*1H
|
| Chemical Name |
3-(1H-imidazol-5-yl)propyl N'-[(4-chlorophenyl)methyl]carbamimidothioate;dihydrobromide
|
| Synonyms |
Clobenpropit HBr; Clobenpropit dihydrobromide; VUF 9153; VUF-9153; VUF9153;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~265.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.42 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1247 mL | 10.6236 mL | 21.2472 mL | |
| 5 mM | 0.4249 mL | 2.1247 mL | 4.2494 mL | |
| 10 mM | 0.2125 mL | 1.0624 mL | 2.1247 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
